Viral Hepatitis News

SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.

As you read these words, you may be learning for the first time about hepatitis delta virus — a lesser-known type of hepatitis that is potentially life-threatening.

Patients who tested positive for hepatitis D virus antibodies were at greater risk for developing hepatocellular carcinoma and other adverse liver-related outcomes, often at a young age, according to study results.

From 2010 to 2020, less than half of perinatally exposed infants were tested for hepatitis C virus, according to a study, but experts are hopeful that new early testing guidelines will ensure more infants are screened and treated.

Hepatitis B e-antigen seroconversion in childhood and low hepatitis B surface antigen titers after seroconversion independently predicted functional cure in chronic HBV-infected patients followed from childhood through adulthood.

In a Healio video exclusive, Edward V. Loftus Jr., MD, warned that, despite being the smallest virus capable of causing human disease, hepatitis delta virus holds an outsized global impact as the most severe form of viral hepatitis.

Over recent years, there has been increased interest and attention to hepatitis delta virus, as we are beginning to understand that this is a real problem that at the moment is under-addressed and under-identified.

Despite being the smallest virus capable of causing human disease, it is estimated that up to 80% of patients with hepatitis delta virus will progress to liver cirrhosis and more than 50% will die of liver disease within 10 years of diagnosis.